Mariana M. Dias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mariana M. Dias has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ana Teresa Rufino
LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal
1 shared publication - Beatriz Teixeira
CESAM-Center for Environmental and Marine Studies, Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal
1 shared publication - Carolina Frazão
Centre for Environmental and Marine Studies, Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal
1 shared publication - Catarina de Almeida Custódio
Department of Chemistry CICECO University of Aveiro Campus Universitário de Santiago Aveiro 3810‐193 Portugal
1 shared publication - Duaete Rafael Salgado de Almeida
University of Aveiro TEMA Centre for Mechanical Technology and Automation, Department of Mechanical Engineering Aveiro
1 shared publication - Gil Gonçalves
Centre for Mechanical Technology and Automation (TEMA), Mechanical Engineering Department, University of Aveiro, 3810-193 Aveiro, Portugal
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by Elsevier in Materials Today Bio
- Vol. 39
Redefining 3D cell culture: Human methacryloyl platelet lysates hydrogels for reliable, consistent, and ethical applications
- 9 July 2026
- Published by Elsevier in Materials Today Bio
- Vol. 39
Open AccessRedefining 3D cell culture: Human methacryloyl platelet lysates hydrogels for reliable, consistent, and ethical applications
- Open Access
Optimized Synthesis of Poly(Lactic Acid) Nanoparticles for the Encapsulation of Flutamide
Biopolymeric nanoparticles (NPs) have gained significant attention in several areas as an alternative to synthetic polymeric NPs due to growing environmental and immunological concerns. Among the most promising biopolymers is poly(lactic acid) (PLA), with a reported high degree of biocompatibility and biodegradability. In this work, PLA NPs were synthesized according to a controlled gelation process using a combination of single-emulsion and nanoprecipitation methods. This study evaluated the influence of several experimental parameters for accurate control of the PLA NPs’ size distribution and aggregation. Tip sonication (as the stirring method), a PLA concentration of 10 mg/mL, a PVA concentration of 2.5 mg/mL, and low-molecular-weight PLA (Mw = 5000) were established as the best experimental conditions to obtain monodisperse PLA NPs. After gelification process optimization, flutamide (FLU) was used as a model drug to evaluate the encapsulation capability of the PLA NPs. The results showed an encapsulation efficiency of 44% for this cytostatic compound. Furthermore, preliminary cell viability tests showed that the FLU@PLA NPs allowed cell viabilities above 90% up to a concentration of 20 mg/L. The comprehensive findings showcase that the PLA NPs fabricated using this straightforward gelification method hold promise for encapsulating cytostatic compounds, offering a novel avenue for precise drug delivery in cancer therapy.
Open AccessOptimized Synthesis of Poly(Lactic Acid) Nanoparticles for the Encapsulation of Flutamide
Biopolymeric nanoparticles (NPs) have gained significant attention in several areas as an alternative to synthetic polymeric NPs due to growing environmental and immunological concerns. Among the most promising biopolymers is poly(lactic acid) (PLA), with a reported high degree of biocompatibility and biodegradability. In this work, PLA NPs were synthesized according to a controlled gelation process using a combination of single-emulsion and nanoprecipitation methods. This study evaluated the influence of several experimental parameters for accurate control of the PLA NPs’ size distribution and aggregation. Tip sonication (as the stirring method), a PLA concentration of 10 mg/mL, a PVA concentration of 2.5 mg/mL, and low-molecular-weight PLA (Mw = 5000) were established as the best experimental conditions to obtain monodisperse PLA NPs. After gelification process optimization, flutamide (FLU) was used as a model drug to evaluate the encapsulation capability of the PLA NPs. The results showed an encapsulation efficiency of 44% for this cytostatic compound. Furthermore, preliminary cell viability tests showed that the FLU@PLA NPs allowed cell viabilities above 90% up to a concentration of 20 mg/L. The comprehensive findings showcase that the PLA NPs fabricated using this straightforward gelification method hold promise for encapsulating cytostatic compounds, offering a novel avenue for precise drug delivery in cancer therapy.